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Background: Herpes zoster (HZ) is a self-limiting painful skin rash affecting mostly individuals from 50 years of age.
The main complication is postherpetic neuralgia (PHN), a long-lasting pain after rash has resolved. A HZ-vaccine has
recently been licensed in Europe for individuals older than 50 years. To support an informed decision-making for a
potential vaccination recommendation, we conducted a health economic evaluation to identify the most cost-
effective vaccination strategy.
Methods: We developed a static Markov-cohort model, which compared a vaccine-scenario with no vaccination.
The cohort entering the model was 50 years of age, vaccinated at age 60, and stayed over life-time in the model.
Transition probabilities were based on HZ/PHN-epidemiology and demographic data from Germany, as well as
vaccine efficacy (VE) data from clinical trials. Costs for vaccination and HZ/PHN-treatment (in Euros; 2010), as well as
outcomes were discounted equally with 3% p.a. We accounted results from both, payer and societal perspective.
We calculated benefit-cost-ratio (BCR), number-needed-to-vaccinate (NNV), and incremental cost-effectiveness ratios
(ICERs) for costs per HZ-case avoided, per PHN-case avoided, and per quality-adjusted life-year (QALY) gained.
Different target age-groups were compared to identify the most cost-effective vaccination strategy. Base-case-
analysis as well as structural, descriptive-, and probabilistic-sensitivity-analyses (DSA, PSA) were performed.
Results: When vaccinating 20% of a cohort of 1 million 50 year old individuals at the age of 60 years,
approximately 20,000 HZ-cases will be avoided over life-time. The NNV to avoid one HZ (PHN)-case was 10 (144).
However, with a BCR of 0.34 this vaccination-strategy did not save costs. The base-case-analysis yielded an ICER of
1,419 (20,809) Euros per avoided HZ (PHN)-case and 28,146 Euros per QALY gained. Vaccination at the age of 60
was identified in most (sensitivity) analyses to be the most cost-effective vaccination strategy. In DSA, vaccine price
and VE were shown to be the most critical input-data.
Conclusions: According to our evaluation, HZ-vaccination is expected to avoid HZ/PHN-cases and gain QALYs to
higher costs. However, the vaccine price had the highest impact on the ICERs. Among different scenarios, targeting
individuals aged 60 years seems to represent the most cost-effective vaccination-strategy.
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Before implementation of routine childhood varicella
vaccination in 2004, the lifetime risk of acquiring a
varicella-zoster-virus (VZV) infection in Germany was
almost 100% [1,2]. Children under 10 years of age were
predominantly affected by the infection, which clinically
manifests as chickenpox (varicella). After recovery from
varicella, the virus remains latent life-long in individual’s
dorsal root ganglia [3]. Later in life, the VZV can reacti-
vate and manifest as shingles (herpes zoster, HZ) as a re-
sult of decreasing VZV-specific T-cell-immunity [4,5].
Natural waning immunity and other causes like psycho-
logical stress or immunosuppression can contribute to a
VZV-reactivation, too [6].
HZ is a painful and self-limiting skin-rash that lasts
approximately four weeks [7-9]. The main complication
of HZ is postherpetic neuralgia (PHN) a long-lasting
pain in the formerly HZ-affected skin region after rash
has resolved [5,10-12]. Both, HZ and PHN cause limita-
tions on quality of life (QoL) [13-16]. Approximately 20-
30% of individuals experience at least one HZ-episode in
their life [17]. The risk and burden of HZ increase with
age, most cases being 50 years and older [4,18-21]. In
Germany, the risk in this age-group is estimated at 9 per
1,000 persons per year (PY), which is comparable to
other industrialized countries [21-23]. Estimates for the
proportion of HZ-patients developing PHN range be-
tween 6 and 7% [21,23]. The options for therapy and
prevention of HZ and PHN are limited [24-28].
In 2006, the first vaccine for the prevention of HZ and
PHN for people 50 years of age and older was licensed
in Europe [12]. This live-attenuated vaccine demon-
strated its efficacy in two double-blinded, placebo-
controlled randomized trials (RCT), which included
healthy individuals aged >50 years [29,30]. Another HZ-
vaccine candidate is currently tested in clinical phase III
trials and might be available in the near future [31]. As
of June 2013, the licensed vaccine was not yet available
on the market in most European countries. However,
the market launch in Germany might be expected soon.
To support an informed decision-making of a potential
vaccine-recommendation by relevant authorities, we
performed a health economic evaluation of routine HZ-




We developed a static Markov-cohort model, since no
transmission dynamics like herd protection after imple-
mentation of HZ-vaccination can be expected [32]. In
the model, a scenario with routine HZ-vaccination in
the German statutory health insurance (SHI) system
(‘vaccine-scenario’) was compared with the currentsituation without HZ-vaccination (‘status quo’). The SHI
system covers approximately 85% (70 million indivi-
duals) of the German living population [33]. According
to the disease course, we modeled five Markov-states:
‘Healthy’, ‘Herpes zoster’, ‘PHN’, ‘Healthy after Disease’,
and ‘Death’ (Figure 1). States were connected by transi-
tion probabilities (confer arrows and respective Greek
letters shown in Figure 1 and Table 1). The state ‘Death’
was an absorbing state and ‘PHN’ as well as ‘Healthy
after Disease’ were ‘tunnel’-states such that individuals
stayed a fixed time in these states. We defined the
Markov-cycle length to be three months, since HZ usu-
ally lasts about one month and a potential PHN occurs
proximately three months after rash onset and lasts nine
months by average [7-9,12,13,34-41]. The model started
with a cohort of 1 million individuals at 50 years of age
with a life-long time-horizon. For each scenario we
calculated the number of HZ-cases and PHN-cases, as
well as quality-adjusted life-years (QALYs). Based on the
accounted costs we calculated the benefit-cost ratio
(BCR) comparing the two scenarios. In addition, we
calculated the number-needed-to-vaccinate (NNV) and
incremental cost-effectiveness ratios (ICERs) accounting
for costs per HZ- and PHN-case avoided and per QALY
gained. We modeled the payer perspective (PP), which
includes only direct costs from the view of the SHI as
well as the societal perspective (SP), which includes




When considering a new vaccine in health economic
evaluations, the epidemiology of the target disease is one
of the most critical input factors. For our model, HZ- and
PHN-related incidence data specific for the German con-
text were derived from a recent retrospective data analysis
in Germany [21]. The anonymized data set of AOK Hesse
(SHI funds) contained about 240,000 insured individuals
including their diagnoses- and service utilization-data for
the year 2004 to 2009. Acute outpatient HZ-cases were
identified via ‘International Statistical Classification of
Diseases’ (ICD-10) B02.*/G53.0 with an additional diagno-
sis reliability ‘assured’ or ‘conjectured’. Inpatient HZ-cases
were identified via German diagnoses-related groups
(G-DRG). PHN was in accordance to other studies defined
as pain persisting at least three month after HZ-onset
[12,29,35-41]. Besides respective ICD-10 codes, HZ-cases
that developed PHN were identified via PHN-specific pain
medication based on German guidelines [28]. About 5.79
HZ-cases per 1,000 person-years (PY) were observed
annually. Of these HZ-cases about 5 % developed PHN
[21]. Exact HZ-incidence and PHN-proportion figures
were provided in Table 2.
Figure 1 Markov-model structure.
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recurrence, i.e. the occurrence of a subsequent HZ-
episode [4,20,44-47]. There are discrepant findings on
the frequency of this phenomenon in the literature.
However, studies suggesting that the risk of HZ-
recurrence is low have a rather short follow-up time
and/or a low number of HZ-patients included [20,44,46].
In contrast, studies with a follow-up period of several
years conclude consistently that the risk of a subsequent
HZ-episode is a critical factor when considering HZ-
related disease burden [4,45,47]. A large study address-
ing specifically the risk of HZ-recurrence, which
involved 1,669 HZ-cases with an average follow-up of
7.3 years, suggests that the incidence of HZ-recurrence
is similar to the incidence of a first HZ-episode [47]. We
have accounted for this risk by using same input-data
for HZ-incidence and HZ-recurrence (see Sections
‘Base-case analysis’ and ‘Structural sensitivity analysis’
for further exemplifications). Incidence of HZ-associated
death was available from a retrospective data-analysis in
Germany [22]. The probability of death due to all causes
by age (‘background mortality’) in the general populationliving in Germany was derived from public statistics of
the federal statistical office in Germany [48] (Table 2).
Utility data
For cost-utility analyses, quality of life (QoL) data were
considered. Since HZ-related QoL and pain intensity data
among HZ- or PHN-patients is lacking for Germany, we
used data from a study by Drolet and colleagues, which
was conducted in a Canadian population of individuals 50
years of age and older without stratification by HZ severity
[14]. This fitted well to our input-data (incidence and
costs), which were derived from all patients without speci-
fication of pain intensity. We informed our model with
the corresponding ‘EQ-5D scores’ (utilities). We fitted the
data by calculating the age-specific average utilities based
on values of day 0 and day 30 as HZ-related utilities, and
the age-specific average based on values of day 90 and day
180 as PHN-related utilities, as defined by Drolet et al.
[14]. For individuals located in the states ‘Healthy’ and
‘healthy after disease’ we chose 1 as a value for baseline
utility in the base-case. To account for vaccine-related
adverse reactions on the QoL, we assumed a utility of 0.99
Table 1 Transition probabilities
State (From state→ To state) Variable Formula
Death
Death→ Death λi =1
Any state→ Death αi = p
BackgroundMortality
i
Status quo [no vaccination]
Healthy




Healthy→ Healthy γi = 1 − αi − βi
Herpes zoster




Herpes Zoster→ PHN εi = 1− αið Þ  1− e−IHZ→PHNi
 
Herpes Zoster→ Healthy after disease ζi = 1 − αi − δi − εi
PHN
PHN→ PHN ηi = χ 1;DPHN½  σð Þ  1−αið Þ
PHN→ Healthy after disease θi = 1 − αi − ηi
Healthy after disease
Healthy after disease→ Healthy after disease κi = χ 1;DRec½ Þ σð Þ  1− αið Þ þ χ DRec ;∞½ Þ σð Þ  γi
Healthy after disease→ Herpes zoster ιi = 1 − αi − κi
Vaccine-Scenario [adapted transition
probability due to vaccine efficacy (VE)]
Healthy
Healthy→ Herpes zoster βiV = βi  1− VEHZi
 
VEi
HZ = χ j;μ½ Þ ið Þ  IVEHZj þ χ μ;∞½ Þ ið Þ  IVEHZj  e−π i−μð Þ
Healthy→ Healthy γiV = 1− αi − βVi
HZ
Herpes zoster→ PHN εiV = εi  1− VEPHNi
 
VEi
PHN = χ j;μ½ Þ ið Þ  IVEPHNj þ χ μ;∞½ Þ ið Þ  IVEPHNj  e−π i−μð Þ
Healthy after disease
Healthy after Disease→ Healthy after disease κiV = χ 1;DRec½ Þ σð Þ  1− αið Þ þ χ DRec ;∞½ Þ σð Þ  γVi
Healthy after Disease→ Herpes zoster ιiV = 1− αi − κVi
p = probability of death with respect to cycle-length; i = age = Start_Age +(n_cycles); χA(x) = Indicator function; σ = Tunnel (counter for cycles staying in state);
DPHN = Duration of PHN; DRec = Duration until Recurrence is possible; v = indicating the vaccine scenario; j = Age at Vaccination; μ = Age at Vaccination plus n
years; I = Age-group specific Incidencefrom_state→to_state with respect to cycle-length; VEi
HZ = Vaccine efficacy protecting against HZ; IVEj
HZ = Initial Vaccine efficacy
protecting against HZ by age at vaccination; VEi
PHN = Vaccine efficacy protecting against PHN by certain age in model; IVEj
PHN = Initial Vaccine efficacy protecting
against PHN by age at vaccination; π = Waning rate with respect to cycle-length.
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generally well tolerated [29,49].
Vaccine characteristics
Vaccine efficacy (VE) as another key factor in this health
economic analysis was utilized carefully. Published data
from the currently licensed live-attenuated vaccine were
considered for VE: data for preventing HZ and PHN in
elderly was derived from the RCT ‘shingles prevention
study’ (SPS) involving almost 40,000 individuals 60 years
of age and older [29]. In this study, the average VE in
preventing HZ was 51.3% and in preventing PHN 66.5%
[29,50]. For HZ-related VE stratified by more precise
age-groups, we considered information from the clinicalbriefing document of the US Food and Drug Adminis-
tration (FDA) [51] as well as a recent RCT in individuals
aged 50–59, where HZ-related VE was 69.8% [30]. As
this RCT did not measure the PHN-related VE, we
adopted this value from the age-group 60–69 years from
SPS (Table 2). A sub-study of the SPS re-enrolled over
14,000 subjects (7,320 vaccine and 6,950 placebo recipi-
ents) in the short-term persistence sub-study (STPS) in
order to assess the persistence of VE over time since
vaccination [52,53]. VE for HZ and PHN was assessed
for the combined SPS and STPS populations as well as
for each year through year 7 after vaccination. The over-
all HZ (PHN)-VE in the SPS+STPS population was
48.7% (64.9%). However, during the 7 year follow-up, a
Table 2 Model input-data
Base-case DSA PSA
HZ PHN HZ PHN
Epidemiology [21]
Age-group Cases/1,000 PY % of HZ-cases 95% CI (Cases/1,000 PY) 95% CI (% of HZ-cases) Triangular
50–59 6.56 3.38 6.12–7.01 2.15–4.61
60–69 9.19 4.92 8.68–9.71 3.73–6.11
70–79 11.24 7.85 11.66–11.82 6.48–9.23
>80 12.76 7.8 11.92–13.61 6.05–9.55
Vaccine efficacy (%) [29,30,50,51]
Age-group 95% CI 95% CI Beta
50–59 69.8 65.7* 54.1–80.6 20.4*–86.7*
60–64 65.4 65.7 55–70.9 20.4–86.7
65–69 62.58 65.7 55–70.9 20.4–86.7
70–74 43.74 66.8 25–48.1 43.3–81.3
75–79 36.51 66.8 25–48.1 43.3–81.3
80–84 20.09 66.8 25–48.1 43.3–81.3
>85 13.22 66.8 25–48.1 43.3–81.3
EQ-5D utilitiesª [14]
Age-group 95% CI 95% CI Beta
50–60 0.68 0.725 0.61–0.745 0.63–0.815
61–70 0.6 0.68 0.525–0.67 0.605–0.76
>70 0.62 0.64 0.550.69 0.57–0.705
Treatment costs per case (€) [21]
Perspectives/Age-group Payer Societal Payer Societal Payer 95% CI Societal 95% CI Payer 95% CI Societal 95% CI Gamma
50–59 193 570 872 1,339 148–245 495–651 289–1,940 436–3,065
60–69 226 338 1,349 2,137 179–270 281–397 714–2,125 975–3,625
70–79 203 214 1,172 1,218 159–252 169–263 717–1,785 750–1,863
>80 320 331 642 676 249–394 259–408 251–1,157 270–1,207
Background mortality [probability (%) p.a.]***
[48]









Base-case DSA [lower/higher value] PSA
Vaccine Price/dose (€) [59] 140.48 70.24 210.72 Normal
Vaccine administration costs (€)** 7 5.20 10.81 Normal
Discount rate (% p.a.) 3 0 10
Waning immunity rate (% p.a.) [56] 8.3 0 20 Beta
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Table 2 Model input-data (Continued)
Coverage (%) assumption 20 - -
HZ susceptibility**** (%) [2] 100 - -
EQ-5D utilities for healthy
individuals (age in years)
1(all ages) 0.859b (41–60) 0.7684b (61+)
DSA Deterministic Sensitivity Analysis, PSA Probabilistic Sensitivity Analysis displays the age related probability distribution of respective input-data used in
Monte Carlo simulations, CI confidence interval, *value adopted from age 60; **vaccine administration costs adopted from pneumococcal vaccination
(adjusted from different regional values); ***Values adjusted to table’s age-groups; ****All individuals in the model were susceptible for developing HZ due to
high seroprevalence of varicella-zoster virus in the German population; ªAdjusted from Drolet et al. [14]; bGender unspecific values adjusted from linear model in
Hinz et al. [61]; €, Euro in 2010 price levels; PY persons per year.
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concerning PHN were observed. HZ-related VE ranged
through years between 62 and 30.6%; PHN-related VE
alternated between 83.4 and 32% [53]. Yet, these results
were not statistically significant since confidence inter-
vals overlapped. Thus, we assumed a stable VE for 10
years following vaccination. However, to use conserva-
tive assumptions, we considered in our model a ‘waning’
of vaccine induced immunity as done elsewhere
[40,54,55]. After 10 years of stable VE, HZ- and PHN-
related VE decreased exponentially by 8.3% per year
(Table 1, Table 2, and Figure 2) [56]. Coverage was
assumed to be 20% since pneumococcal vaccination
coverage among elderly in Germany is with 10-29%
relatively low, and since the HZ-vaccine coverage in the
US was 15.8% in 2011 [57,58].
Cost data
Cost data was derived from the same study where the
incidence data was utilized. Data was stratified by HZ
and PHN, by age-groups, and by perspectives (Table 2).Figure 2 Schematic presentation of waning-immunity after VZV-infec
with/without booster-scenarios. HZ, herpes zoster; PHN, postherpetic neAs all cost values in our model were at Euro 2010 price
levels, we considered the German pharmacy retail price
of HZ-vaccine for the same year reduced by the obliga-
tory pharmacy and manufacturer discounts. Thus, the
HZ-vaccine price per dose in our model was set to
140.48 Euros [59]. We used the mean administration
costs per pneumococcal vaccine dose in Germany in
2010 (7 Euros) as a proxy for HZ-vaccine administration
in the base-case assumption and considered the regional
minimum and maximum values for sensitivity analyses
(SA, Table 2).
All epidemiological, demographic, and VE data were, if
necessary, converted into age-group specific probabilities
or relative risks with respect to the model’s cycle-length
(see Table 1 and Figure 1) [60].
Base-case analysis
In base-case analysis, the model’s start age was set to 50
years and the age of vaccination to 60 years. For inci-
dence and recurrence rates as well as for treatment costs
per case we used the respective point estimators fromtion and after additional vaccination with Herpes-zoster vaccines
uralgia.
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For the tunnel state ‘Healthy after Disease’, we defined
that a recurrence cannot occur within three years (12 cy-
cles) after preceding the first HZ-episode [47]. Further-
more we adjusted the tunnel state ‘PHN’ to keep
individuals three cycles, since the average duration of
PHN is 9 month (confer ‘Model design’ section). The
utility values, waning rate, vaccine price, and vaccine
honorary were set as described in ‘Input data’ section.
For ICER calculation, costs and outcomes were
discounted equally with 3% per annum as suggested in
Germany [42] (Table 2). Additionally we conducted a
‘Break-even’ analysis. For this we used the base-case
conditions to identify the vaccine price at which the
ICERs represent cost-savings.
Univariate deterministic sensitivity analyses
With univariate deterministic sensitivity analyses (DSA)
we investigated the impact of different age-specific
incidences and treatment costs, VE, waning immunity
rates, discount rates, and vaccine prices as well as
administration costs and utility values (Table 2). For
measuring the impact of an absent HZ-recurrence we
set the respective value to zero. To measure the impact
of a high HZ-recurrence, we used the upper limit 95%
confidence interval (CI) of HZ-incidence values and
removed the ‘tunnel’-state condition. Hence, in the latter
scenario a HZ-episode was theoretically possible right
after the previous one. Since in a static model a change
in coverage would not affect the ICERs, we neglected
this variation in the SA. In contrast to the base-case we
changed the age of vaccination from 60 years to 50, 55,
65, 70, 75, and 80 years and stratified the analyses by
outcome and perspective.
Structural sensitivity analysis
In a ‘Best Case Scenario’ we assumed a situation in favor
of the new HZ-vaccine and changed input-data accord-
ingly. We used the higher values of 95% CI of the HZ
and PHN disease-incidences and costs per case. Further-
more, we set the recurrence rate as high as described
before and used the lower utilities for HZ and PHN,
respectively. Higher 95% CI values were taken for VE
whereas the waning rate was set to zero. Vaccine admin-
istration costs were lowered to 5.20 Euros and the
vaccine price by 50%.
The ‘Worst case Scenario’ represented possible least
preferable results. In terms of epidemiology we used the
lower 95% CI estimates of the HZ- and PHN-incidence.
For HZ and PHN-treatment costs we took the lower
95% CI values and neglected recurrence by setting its
probability to zero. We considered higher utilities, an
annual waning rate of 20% and the lower 95% CI
values of the VE. We increased the vaccine price by50% and set the administration costs to 10.81 Euros
per vaccination.
The variation of ‘Duration of stable VE’ aims to reduce
the potential uncertainty associated with the model’s
base-case that considers 10 years of stable VE following
vaccination. Since this is an assumption based on trial
data (see section ‘Vaccine characteristics’) we conducted
analyses where we changed the period of stable VE
following vaccination from 0, 5, 15, to 20 years.
A combined analysis of the impact of different annual
waning immunity rates (1%, 5%, 8.3%, and 20%), dur-
ation of stable VE (0, 5, 10, and 15 years), and the age at
vaccination (50, 60, and 70 years) on the costs per QALY
gained was performed to identify the optimal age at
vaccination.
Furthermore, we implemented different ‘booster sce-
narios’ into the model. Therefore, HZ-vaccinated indi-
viduals were administrated a second dose 20 years after
first HZ-vaccination. This booster was given to 50% of
these formerly HZ-vaccinated individuals located in the
states ‘Healthy’ or ‘Healthy after disease’ within the
vaccine-scenario (Figure 1). Besides additional costs due
to vaccination and a two day reduction of individual’s
QoL because of vaccine related adverse reactions the
booster shot increased the vaccine-induced immunity.
We modeled two oppositional booster scenarios: In
favor for the HZ-vaccine and its booster we assumed in
the ‘Best Case Booster Scenario’ an increase of the
vaccine-induced immunity to the same level as after the
first vaccination (Table 2), and a constant VE for 10
years before the waning with a rate of 1% p.a. began
(Figure 2). In the ‘Worst Case Booster Scenario’ the
booster increased the vaccine induced immunity only to
the respective level of the actual age as presented in
RCTs considering VE (Table 2) and this immunity
diminished immediately by the annual waning rate of
20%. In order to account for the influence of age at
vaccination on the ICERs, we modeled both booster
scenarios not only for the base-case (60 years of age at
vaccination) but also for 50, 70, and 80 years at
vaccination.
To measure the impact of varying ‘duration of PHN’
on ICER (cost per QALY gained), we changed PHN dur-
ation from 9 months (base-case) to 6, 15, and 36 month,
respectively.
In order to assess the impact of a ‘change in baseline
utility’ values for healthy individuals, we used data from
a study conducted in Germany [61]. In this study 2,022
healthy individuals between 16 and 93 years of age were
interviewed using the EQ-5D questionnaire. Further-
more three different accounting models (sum model,
linear model, and a multiplicative model) were used to
calculated values resulting from EQ-5D items. For this
SA we used the age-specific utilities from the linear
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unspecific input-data, we calculated age-specific average
values from both gender (Table 2).
Multivariate probabilistic sensitivity analyses
To identify the robustness of the base-case and the
probability of extreme favorable or unfavorable results
and to get more insights into uncertainties, we perfor-
med multivariate probabilistic sensitivity analyses (PSA)
[62]. We conducted a Monte Carlo simulation with
10,000 runs for each outcome (HZ- and PHN-cases
avoided, QALY gained). The respective input-data were
drawn simultaneously (multivariate) from probability dis-
tributions within the ranges considered in DSA (Table 2).
For guidance purposes four thresholds (20,000, 30,000,
50,000, and 100,000 Euros per QALY gained) representing
different fictitious willingness to pay (WTP) levels were
implemented within the scatter plot of the PSA conside-
ring costs per QALY gained.
External comparison and software
For a proper external comparison of our model results
we considered findings from other international health
economic evaluations. For a better comparison, we
inflated the cost data from other studies to price levels
of 2010 (reference year) within each study’s country
using consumer prices indices and converted these re-
spective amounts by the gross domestic product pur-
chasing power parity (GDP PPP) into Euro amounts
with Germany as reference country based on data from
the Organization for Economic Co-operation and Devel-
opment (OECD) [63,64]. Hence, amounts were presen-
ted in PPP-Euros. Furthermore, we considered thoseTable 3 Results from base-case analyses
a: Overall effects [cohort of 1 million individuals not discounted]
Number of HZ-cases Costs of treatm
Status quo 284,768 127,978,000
Vaccination scenario 264,977 117,948,913
b: Number needed to vaccinate (NNV)
Avoiding one HZ-case 10
Avoiding one PHN-case 144
Gaining one QALY 195
c: Costs and effects in both scenarios of the model






*Benefit-Cost ratio; €, Euro in 2010 price levels.
ICER, incremental cost-effectiveness ratio; HZ, herpes zoster; PHN, postherpetic neuanalyses in respective studies that were similar to our
base-case. Thus, we did not necessarily refer to base-
case results from the other studies in the ‘Discussion’
section.
Software used was: TreeAge® Pro 2012 (TreeAge
Software, Williamstown, MA), Microsoft® Excel 2010
(Microsoft, Redmond, WA), and STATA® 12.1 (StataCorp,
College Station, TX).Results
Base-case results
Vaccinating 20% of individuals in a cohort of 1 million
50 year old persons at the age of 60 years costs almost
30 million Euros. Over the cohort’s lifetime approxi-
mately 20,000 HZ-cases can be avoided, which results
into a reduction of treatment costs by over 10 million
Euros. These figures translate in a BCR of 0.34, which
indicates that HZ-vaccination is not a cost-saving mea-
sure (Table 3a). Ten individuals need to get vaccinated
to avoid one HZ-case and 144 to avoid one PHN-case.
In terms of gaining one QALY, 195 people need to
receive a shot (Table 3b). As indicated by the BCR costs
in the vaccine scenario are higher than in status quo.
This is because besides costs for vaccination, costs for
treatment (however, with a lower probability and there-
fore proportion) do occur in vaccination scenario, too.
The QALY gain is also higher in the vaccination scenario
(Table 3c). Considering the ICERs, the vaccination of 60
year old individuals yield costs of 1,419 Euros per HZ-
case avoided, 20,809 Euros per PHN-case avoided, and
28,146 Euros per QALY gained (Figure 3 and Table 4).
As indicated by the ‘Break-even’ analysis, a price perent (€) Costs of vaccination (€) Total costs (€) BCR*
- 127,978,000
29,496,000 147,444,913 0.34
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Figure 3 Base-case-analyses and variation of age and perspective - ICERs by outcome and age. ICER, incremental cost-effectiveness ratio;
HZ, herpes zoster; PHN, postherpetic neuralgia; QALY, quality adjusted life-year. NOTE: Hatched bars represent base-case analyses.
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http://www.biomedcentral.com/1472-6963/13/359vaccine dose below 26.50 Euros (i.e. >80% below base-
case assumption) would result in potential cost-savings.
Univariate deterministic sensitivity analyses
Considering the age at vaccination, cost-effectiveness is
decreasing (indicated by higher ICERs) between the age
of 55 and 75 years. Due to low VE, vaccination of 80
year old individuals seems least cost-effective, especially
when considering costs per HZ-case avoided (Figure 3a).
In terms of PHN-cases avoided the most cost-effective
age at vaccination is 65 years. However, the base-case
results are only slightly higher (hatched bar in Figure 3b).The lowest ICER with respect to QALYs gained is
represented by the base-case (hatched bar in Figure 3c).
Due to indirect costs occurring in the working population,
the difference between PP and SP is higher between 50 to
60 year old individuals and decreases with increasing age.
The costs of vaccination have the highest impact on
the costs per HZ-case avoided in the DSA (Figure 4a). A
decrease in costs of vaccination, e.g. by 50% per vaccine
dose and to 5.20 Euros administration costs, lowers the
ICER by 63%. In addition, varying the annual discount
rate and annual HZ-recurrence influenced considerably
the ICER (Figure 4a). The low PHN-related VE has a
Table 4 Results from structural sensitivity analyses (discounted)
a: Extreme scenarios and variations in the duration of stable VE
Base-case Extreme scenario
Best case Worst case
ICER by outcome
€/HZ-case avoided 1,419 17 4,595
€/PHN-case avoided 20,809 163 327,691
€/QALY gained 28,146 235 157,845
b: Duration of stable VE [years]
0 5 10 (base-case) 15 20
ICER by outcome
€/HZ-case avoided 2,633 1,800 1,419 1,225 1,123
€/PHN-case avoided 40,300 27,057 20,809 17,708 16,128
€/QALY gained 53,702 36,211 28,146 24,060 21,931
c: Booster scenarios [by age at vaccination in years]
Base-case Best case
50 60 70 80
ICER by outcome
€/HZ-case avoided 1,419 1,080 1,361 2,701 9,372
€/PHN-case avoided 20,809 19,001 19,632 22,931 35,604
€/QALY gained 28,146 30,241 32,173 46,126 93,497
Base-case Worst case
50 60 70 80
ICER by outcome
€/HZ-case avoided 1,419 1,580 1,621 2,792 9,384
€/PHN-case avoided 20,809 29,095 22,643 23,345 35,619
€/QALY gained 28,146 52,628 39,604 47,559 93,565
d: Variations in the length of PHN [month]
6 9 (base-case) 15 36
ICER by outcome
€/QALY gained 31,741 28,146 23,048 4,149
€, Euro in 2010 price level.
ICER, incremental cost-effectiveness ratio; HZ, herpes zoster; PHN, postherpetic neuralgia; QALY, quality adjusted life-year; VE, vaccine efficacy.
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http://www.biomedcentral.com/1472-6963/13/359great impact on the costs per PHN-case avoided and
increases the respective ICER by factor 4, which repre-
sents the general high impact of variations in PHN-
related VE in health economic analyses (Figure 4b).
Whereas costs of vaccination, annual discounting, and
HZ-recurrence have the highest impact on ICERs related
to PHN-case avoided and costs per QALY gained, HZ-
incidence and treatment costs have only little impact on
ICERs (Figure 4).
Structural sensitivity analysis
In the best-case scenario cost-saving levels are almost
reached. In contrast, the scenario least in favor for the
vaccine accounts for very high ICERs (Table 4a). The
variation of the period of stable VE following vaccination
shows the logical negative correlation between durationof stable VE and ICERs. The lower the duration of stable
VE following vaccination, the higher the ICERs are.
ICERs decrease by factor 2.5 when increasing the dur-
ation from 0 to 20 years (Table 4b). Considering a var-
iety of duration of vaccine induced protection and
waning immunity rates, the analysis suggests that age 60
is most likely the optimal age at vaccination if the annual
waning immunity rate is ≥5% (Figure 5). If the waning
immunity rate is below 5%, age 50 seems to be the opti-
mal age at vaccination. Furthermore, a high waning rate
(≥8.3%) and a low duration of stable VE (<10 years)
causes lower ICERs when vaccinating at age 70 when
compared to vaccinating at age 50 (Figure 5a and 5b).
With a higher duration of stable VE the impact of a
varying waning immunity rate on ICERs by age at vac-
cination (Figure 5d).
Figure 4 Deterministic sensitivity analysis by outcomes from societal perspective. ICER, incremental cost-effectiveness ratio; HZ, herpes
zoster; PHN, postherpetic neuralgia; QALY, quality adjusted life-year; p.a., per annum. NOTE: Black bars represent lower input values.
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http://www.biomedcentral.com/1472-6963/13/359The best case booster scenario is more cost-effective
than the worst-case scenario independently from age at
vaccination. However, the age-specific differences be-
tween both scenarios become smaller with increasing
age: While ICERs at age 50 at vaccination differ between
30 to over 40% between both scenarios, the ICERs at age
80 at vaccination are almost equal (<0.1%, Table 4c). In
Table 4d ICERs are shown by different duration of PHN.
An increase from 6 to 9 month reduces ICERs by over
10%; an increase from 9 to 15 month causes a reductionby almost 20%. A PHN-duration of 3 years instead of 9
month decreases the ICER by almost 85% (Table 4d).
Using age-specific baseline utility values causes an in-
crease of about 30% compared to base-case figures. The
ICER results in 36,629 Euros per QALY gained.
Multivariate probabilistic sensitivity analyses
The distributions of costs and respective outcome are
presented in Figure 6. In the situation of HZ-cases
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Figure 5 Structural sensitivity analysis: impact of duration of stable vaccine efficacy (VE), annual waning of immunity and age at
vaccination on cost per QALY gained. QALY, quality adjusted life-year; SP, societal perspective. NOTE: Hatched bars represent base-case analyses.
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http://www.biomedcentral.com/1472-6963/13/359median ICER of 1,277 (95% CI 1,260 - 1,296) €/HZ-case
avoided is about 10% lower than the respective base-case
ICER. Approximately 3% of results are under the x-axis,
representing cost-saving figures. In terms of costs per
PHN-case avoided the results are distributed more
widely with 1% in the cost-saving area. Compared to the
PHN-related base-case the ICER of PSA is about 6%lower and resulted in 19,625 (95% CI 19,350 – 19,889)
€/PHN-case avoided (Figure 6b). The scope of variation
in cost per QALY gained reaches from cost-saving (2.5%)
to less effective (<1%). Considering the costs per QALY
gained, the calculated median ICER of 25,831 (95% CI
25,369 – 26,210) is about 8% lower than the ICER in
base-case analysis (Figure 6c). The threshold 20,000
Figure 6 Scatter plot: probabilistic sensitivity analysis by outcome. ICER, incremental cost-effectiveness ratio; HZ, herpes zoster; PHN,
postherpetic neuralgia; QALY, quality adjusted life-year; incr., incremental. NOTE: societal perspective; 10,000 Monte Carlo simulations.
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http://www.biomedcentral.com/1472-6963/13/359(30,000) Euro per QALY gained indicates that about 36%
(60%) of all PSA results in Figure 6c are below the thresh-
old. The higher WTP of 50,000 and 100,000 Euros/QALY
gained, respectively, increases the proportion (87% and
99%) of PSA results located below the fictive thresholds(Figure 6c). When considering means instead of median
values, the deviations between the respective PSA ICERs
and the base-case ICERs are lower. Since the PSA ICERs
are lower, our base-case assumptions as well as the base-
case results are rather conservative.
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We developed a static Markov-model and conducted
various SA to assess the cost-effectiveness of routine
HZ-vaccination in Germany and to identify the most
cost-effective strategy when targeting specific age-groups
for vaccination. HZ-vaccination of 20% individuals of a
cohort of 1 million 50 year old persons at age 60 would
avoid 20,000 HZ-cases and reduce the overall HZ-
treatment costs by 10 million Euros. However, with a
BCR of 0.34 for the base-case, our results show that vac-
cination against HZ and PHN is not a cost-saving meas-
ure. Univariate analyses revealed that the price had the
greatest impact on ICERs in the DSA. In the break-even
analysis with all other variable set at base-case scenario,
a price per vaccine dose of <26.50 Euros caused cost-
savings.
Varying several variables in favor for the vaccine (in-
cluding a 50% reduction in the price per vaccine dose to
70 Euros) the intervention becomes almost cost-saving.
However, under least favorable conditions (low estimates
for HZ/PHN-related incidence and treatment costs, low
HZ-recurrence rate, high utilities, low VE, a high waning
immunity rate, high vaccine administration costs, and a
high vaccine dose price) the model accounts very high
ICERs. In general, health economic evaluations of new
vaccines are often impacted by two important input
factors: incidence of the target disease and VE. However,
since the incidence data are rather reliable and range
within narrow CIs, the wide ranges of VE (especially for
the protection against PHN), which are based on trial
data, mainly force the differences of these two extreme
scenarios. Furthermore, the variation of the vaccine price
(−50% vs. +50%) and the variation of disease recurrence
seem to influence the ICERs, too. However, these two
extreme scenarios of varying several input parameter
either in favor for the vaccine or under least favorable
conditions, can be seen as unlikely outer boundaries of
the whole SA’s scope.
Due to decreasing VE by age, an increasing age at vac-
cination usually leads to higher ICERs indicating a lower
cost-effectiveness. However, before the age of 60 the
ICERs are not necessarily more favorable, due to lower
HZ and PHN-related incidence and assumed waning im-
munity. Hence, targeting persons aged 60 years is likely
the most cost-effective vaccination strategy. The vari-
ation in the annual waning rate of vaccine-induced im-
munity had rather limited impact on the ICERs. Altering
the period of stable VE following vaccination from 0 to
20 years produces a relative wide array of ICERs. The
combined analysis of varying waning immunity rates and
durations of stable VE has a rather high impact on
ICERs by age at vaccination. However, this analysis
confirms that age 60 seems to be the optimal age at
vaccination if the annual waning rate is ≥5%. The boosterscenarios showed an increasing similarity between best
and worst booster scenario with increasing age at vaccin-
ation. This confirms the assumption that independently
from how a fictitious booster scenario is designed age of
vaccination is one of the most relevant factors. The most
cost-effective age of vaccination changes from 50 to 60,
when moving from best to worst booster scenario. A vari-
ation of PHN-duration (6–15 month) had a moderate
impact in ICERs. Whereas an extreme extension of PHN-
duration up to 3 years downsizes the costs per QALY
gained enormously. However, since recent studies confirm
an average PHN-duration of several month, our base-case
assumption of 9 month seems to be justified [29,65,66].
In terms of internal validity, we compared the epi-
demiology reported in the literature for Germany (used
as model input parameter) and the model results. The
model slightly overestimated HZ and accounted less
than one percent more HZ-cases per age-group than
represented by input-data. Regarding PHN-cases, the
model calculated 4% more PHN-cases in age-groups 50
to 60 years. In older age-groups the overestimation was
less than 1%. When implementing vaccination into the
model, the accounted cases were reduced according to
the VE implemented into the model. Thus, the model’s
internal validity can be considered as good.
To date there is no other health economic evaluation of
the HZ-vaccine from Germany. However, we identified 14
studies from other European countries [17,34,40,54,67-71]
and North-America [56,72-75]. We found a wide range in
vaccine prices from 43.85 to 438.5 PPP-Euros in one US
study [72] and 81 to 147.32 PPP-Euros in the other stud-
ies. From SP for vaccination of individuals of 60 years re-
sults ranged from cost-savings [72] to 130,097 PPP-Euros
per QALY gained [73]. From PP ICERs ranged from 6,809
[34], 1,200–46,968 [54] to 40,050 PPP-Euros per QALY
gained [68]. Our base-case results range well within these
international findings. However country-specific issues
like vaccine-price, disease epidemiology, price levels, and
treatment pathways as well as model-specific issues like
model structure, specific assumptions, and dealing with
uncertainty hinder a full comparability. Hence, more uni-
form methods in studies are needed to make results more
comparable [76].
One limitation of our health economic model is the
absence of utility-data considering the impact on health
related QoL caused by HZ and PHN specific for Germany.
Instead, we used data derived from a Canadian study
without country-specific adaptation, which might not
necessarily represent the real impact of HZ/PHN on QoL
in Germany [14]. Other studies have reported a higher
limitation on QoL caused by PHN [13,77]. Thus, the
utilized values in our model might underestimate the
impact on QoL due to PHN, whereas the HZ utilities used
in our model might overestimate the impact of HZ on
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varying respective utility values within SAs. Furthermore,
we set the baseline utility value for healthy individuals in
base-case to 1. Thus, the impact of HZ and PHN and
therefore the effect of the vaccine might be overestimated,
since age-specific utilities among elderly tend to be lower
than 1. Even though for health economic evaluation the
utilization of accurate utility data for QoL assessments is
critical, in Germany age-specific utility data for healthy
but also for the most indications are scarce since cost-
utility analyses do not have the relevance in decision-
making in Germany as in other countries. We identified
in a literature search in total five studies evaluating the
QoL among healthy individuals in Germany [61,79-82].
Since all studies have certain limitations (e.g. only visual
analog scale values was reported, no age-specific values
reported, small study sample) we decided against using
values of one of these studies for baseline utility values
within the base-case analysis. However, by considering
age-specific baseline utility values in SA we provided
insights into this factor. The cost data used in the model
were derived from a database from one large regional SHI
in Germany and might not necessarily be representative
for the whole population living in Germany. However,
since countrywide treatment guidelines for HZ and PHN
exist and since prices are mandatory for all SHIs in
Germany, we believe that the utilization of these input-
data is justified and representative. Furthermore our
incidence data included both immune-competent and
incompetent individuals. Since the live-attenuated vaccine
is licensed for immune-competent individuals only, the
incidence figures used in the model might be slightly
overestimated. Our treatment cost input-data did not
include privately covered expenditures for health-care
services and over the counter drugs. Hence, costs from SP
might be underestimated. However, since HZ and PHN-
treatments are usually covered by the SHI, we suspect that
the level of underestimation is low. As evidence was
lacking concerning the duration and waning of vaccine-
induced immunity, we had to make a few assumptions but
included them in the SA. Finally, a real cost-effectiveness
threshold concerning the WTP does not exist for the
German health-care system. Therefore especially the
ICERs and PSA results on costs per QALY gained have to
be interpreted with caution. However, when comparing
different age-groups to be targeted by routine HZ-
vaccination and when comparing different scenarios (e.g.
with and without booster vaccination), the lack of a cost-
effectiveness threshold for Germany does not constitute a
relevant limitation.
Our model provides valuable analyses and insights
when considering the implementation of an efficient
strategy for the prevention of HZ and PHN, and it will
guide decision-making when developing a vaccinationrecommendation for Germany. First, this model reflects
the efficacy of the vaccine quite well, since the HZ- and
PHN-definitions as well as age-strata used in this model
were similar to those used in the clinical-trials [21,29].
HZ-cases with a clinical diagnosis but also with a
‘suspected’ diagnosis were included in both data-sets.
Second, the definition of PHN in the clinical trial was
pain persisting more than 90 days after rash onset. This
matches exactly with the definition in our input-data, in
which HZ-cases became PHN-cases when they were di-
agnosed or received a PHN-specific medication at least
three month after HZ-diagnosis. Second, a further
strength of our analysis is the intensive parameterization
during modeling. The base-case and the SAs demon-
strate that on the one side a careful selection of reliable
input-data is important, but on the other side a wide
range of SAs has to be conducted to reduce uncertainty
within model results. Especially HZ- and PHN-related
incidence and VE have to be incorporated with caution,
since these factors influence the analyses considerably.
However, for our model incidence data were utilized
from a large study recently conducted in Germany.
These data correspond well with results from a nation-
wide incidence study in Germany and another retro-
spective data analysis in Germany, but also with study
results from other countries [17,20,21,23,36,37,83-85].
Thus, this incidence input-data can be regarded as
rather robust. SAs with variations of these data within
the respective CIs have little impact on our results.
However, vaccine characteristics are based on a less rich
data fundament. While data on the VE in individuals
from the age of 50 years is available, data on the
duration of vaccine-induced protection and waning rates
of vaccine-induced immunity is lacking and assumptions
had to be made. Therefore, VE data were analyzed in
SAs to assess the associated uncertainty. Based on one
clinical-trial we assumed the period of stable VE follow-
ing vaccination to be ten years. Since this assumption
carries some uncertainty, we conducted a structural SA
in which we varied the period of stable VE in order to
assess the associated impact on results. Furthermore,
evidence on the exact relative annual waning rate was
utilized from literature. To analyze the impact of waning
on ICERs we neglected the existence of a waning rate in
one scenario and then subsequently increased it within
SAs. A combined sensitivity analysis of varying waning
immunity rates and durations of stable VE illuminated
their combined impact on the optimal age at vaccin-
ation. Going one step beyond, we analyzed also the
potential impact of differently designed fictitious booster
scenarios on the results. This enables to assess booster
scenarios way before evidence on the potential need for
booster is established [86]. Finally, the SA in respect to
HZ-recurrence shows a considerable impact of this
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recurrence has a lower impact than considering a high
HZ-recurrence. This analysis shows that there is an
urgent need to establish more evidence on HZ-
recurrence on the long term view. Since HZ-recurrence
but also HZ-booster vaccination are important param-
eters when conducting a health economic evaluation
of HZ-vaccination in a given country, we believe that
our results are also of high interest to other countries
that consider the introduction of routine HZ-vacci-
nation in their health-care systems. For our study we
were able to use numerous country-specific input-
data of high quality.
Conclusion
Routine HZ-vaccination in the elderly is estimated to
avoid a substantial number of HZ- and PHN-cases in
Germany. However, under base-case assumptions the
costs of vaccination are unlikely to be compensated by
lower treatment costs. The vaccine price was identified
to be crucial when considering overall cost and ICERs.
In view of these findings, a responsible pricing seems
needed. Targeting individuals aged 60 years is likely to
be the most cost-effective vaccination strategy for the
prevention of HZ and PHN in Germany. If another HZ-
vaccine product becomes available on the market in the
future, a comparative health-economic evaluation can be
conducted by utilizing our model. However, results from
head-to-head VE comparisons would be desirable for
such an analysis.
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